An Exploratory stuDy of effectIveneSs and Safety of rivarOxaban in Patients With Left VEntricular… (NCT04970381) | Clinical Trial Compass
CompletedNot Applicable
An Exploratory stuDy of effectIveneSs and Safety of rivarOxaban in Patients With Left VEntricular Thrombus (R-DISSOLVE)
China75 participantsStarted 2020-09-27
Plain-language summary
To study the effect of rivaroxaban anticoagulant therapy for 12 weeks in patients with left ventricular mural thrombus by contrast echocardiography before and after treatment, so as to provide basis and foundation for further study and treatment selection in the future; To provide further relevant data for the treatment outcome, treatment duration and influencing factors of left ventricular mural thrombosis; It is of great sociological and health economic significance to find more effective and safe anticoagulant treatment strategies for patients with left ventricular mural thrombosis, which will reduce the incidence of embolism and bleeding.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Patients over 18 years old;
✓. Patients with left ventricular thrombus newly found by body surface ultrasound less than or equal to 3 months before selection, with no limitation on basic diseases;
✓. Patients who received standard anticoagulant therapy for less than 4 weeks before enrollment did not use antiplatelet drugs or only used single antiplatelet drugs;
✓. The patients voluntarily joined the study and signed the informed consent.
Exclusion criteria
✕. Patients with contraindications to rivaroxaban anticoagulation therapy;
✕. Patients with a history of acute pulmonary embolism or deep venous thrombosis within a week need intensive anticoagulant therapy;
✕. Patients with history of hemorrhagic stroke within one week;
✕. Patients with cardiac benign and malignant tumors;
✕. Aspirin and P2Y12 receptor antagonists should be kept;
What they're measuring
1
Number of Participants With Left Ventricular Thrombus Resolution at 12 Weeks/Number of Participants at 12 Weeks
Timeframe: 12 weeks
Trial details
NCT IDNCT04970381
SponsorChina National Center for Cardiovascular Diseases
✕. In patients with severe hepatic and renal insufficiency, alanine aminotransferase \> 3 times the upper limit and total bilirubin \> 2 times the upper limit, creatinine clearance rate \< 15ml / min / 1.73m2;
✕. The patient's history of intracerebral hemorrhage and active hemorrhage was 8 months;
✕. Patients with hematological diseases, hemoglobin \< 100g / L, platelet \< 80 x 10\^9 / L;